



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January - March 2011

Warrington DAT

Quarter 4 2010/11

Martin Chandler and Steven Griffith

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the NDTMS and DIP teams for their valuable support. We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
2nd Floor, Henry Cotton Campus,
15-21 Webster Street, Liverpool.
L3 2ET

(0151) 231 4349

m.chandler@ljmu.ac.uk

Steven Griffith
IAD Researcher

(0151) 231 4309

S.W.Griffith@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	2
Table 1: Individuals assessed, by Gender & Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Probation	4
Needle and Syringe Programmes (NSPs)	5
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users Omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users Omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users Omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted	
Table 12: Main Drug of Use for New NSP Clients, by Gender	
Table 13: Main Drug of Use for All NSP Clients, by Gender	
Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender	
Table 15: Main Drug of Use, for New NSP Clients, by Age Group	
Pharmacy	11
Table 16: Individuals by Gender	
Table 17: Individuals by Site	
Table 18: Individuals by Age Group	
Table 19: Main drug of Use for All PNSP Clients, by Gender	
Table 20: Year to Date; by Gender & Age Group	
Combined	13
Table 21: Individuals in Agency and Pharmacy NSP, by Gender	
Table 22: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users omitted	
Table 23: Individuals in Agency and Pharmacy NSP, by Age Group	
Table 24: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users	

omitted

Table 25: Year to Date, by Gender & Age Group

Table 26: Combined Pharmacy and Agency NSP Total Syringes Provided

NSP Service Activity Summary **15**

Table 27: All NSP transactions by NSP Type

Fig 1: NSP Service Activity; Transactions by NSP Type

Table 28: NSP Transactions, Attributable Data

Table 29: PNSP Transactions and Individuals by Site

Table 30: All NSP Individuals by NSP Type

Fig 2: NSP Service Activity; Individuals by NSP Type

National Drug Treatment Monitoring System (NDTMS) **17**

Table 31: Individuals in Contact with Treatment Services, by Gender

Table 32: Year to Date, by Gender

Table 33: Individuals in Contact with Treatment Services, by Age Group

Table 34: Year to Date, by Age Group

Table 35: Ethnicity of Individuals in Contact with Treatment Services

Table 36: Individuals in contact with Treatment Services, by Main Drug of Use

Combined Datasets **20**

Table 37: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 38: Year to Date Problem Drug Users, by Gender & Age Group

Cross Matched Datasets **21**

Fig 3: Crossover between Agency NSP and NDTMS datasets

Fig 4: Crossover between Pharmacy NSP and NDTMS datasets

Fig 5: Crossover between YTD Agency NSP and NDTMS datasets

Fig 6: Crossover between YTD Pharmacy NSP and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2010/11)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period. Data are based on initial contact in court or custody suites representing a sub section of the full DIP dataset, further information is available from the IAD on request.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	17	85.0
Female	3	15.0
Age Group		
Under 18	0	0.0
18-19	0	0.0
20-24	1	5.0
25-29	5	25.0
30-34	4	20.0
35-39	7	35.0
40-44	3	15.0
45+	0	0.0
Total	20	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0.0	0	0.0	0	0.0
18-19	4	5.1	0	0.0	4	4.5
20-24	6	7.7	1	9.1	7	7.9
25-29	15	19.2	2	18.2	17	19.1
30-34	10	12.8	4	36.4	14	15.7
35-39	26	33.3	1	9.1	27	30.3
40-44	16	20.5	2	18.2	18	20.2
45+	1	1.3	1	9.1	2	2.2
Total	78	100	11	100	89	100

Table 3: Reported Main Drug(s)* of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	1	0	0
Benzodiazepines	0	0	0
Cannabis	0	0	0
Crack	0	0	0
Cocaine	2	1	0
Ecstasy	0	0	0
Heroin	10	3	3
Methadone	0	0	0
Other	0	0	0

0 individuals did not report a main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily, Weekly or Monthly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION

Quarter 4 (2010/11)

NB: Due to ongoing issues we are unable to provide Probation data for this report. This situation is being resolved and we anticipate being able to include this section in future reports. ASRO reporting is provided as usual.

Current Quarter; ASROs

- 11 ASROs were commenced during Q4
- 11 Individuals commenced ASROs during Q4
- 5 ASROs were terminated during Q4
- 5 Individuals had their ASROs terminated during Q4

NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2010/11)

Introduction

Data are collected directly from needle and syringe programmes (NSPs) including Warrington YMCA. Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	43	97.7
Female	1	2.3
Total	44	100
All Clients		
Male	140	98.6
Female	2	1.4
Total	142	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	3	75.0
Female	1	25.0
Total	4	100
All Clients		
Male	18	90.0
Female	2	10.0
Total	20	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	3	6.8	5	3.5
20-24	18	40.9	3	26.1
25-29	10	22.7	33	23.2
30-34	5	11.4	22	15.5
35-39	4	9.1	20	14.1
40-44	2	4.5	14	9.9
45+	2	4.5	11	7.7
Total	44	100	142	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	25.0	2	10.0
25-29	1	25.0	4	20.0
30-34	0	0.0	3	15.0
35-39	1	25.0	5	25.0
40-44	0	0.0	3	15.0
45+	1	25.0	3	15.0
Total	4	100	20	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	5	3.6	0	0.0
20-24	37	26.4	0	0.0
25-29	31	22.1	2	100
30-34	22	15.7	0	0.0
35-39	20	14.3	0	0.0
40-44	14	10.0	0	0.0
45+	11	7.9	0	0.0
Total	140	100	2	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	2	11.1	0	0.0
25-29	2	11.1	2	100
30-34	3	16.7	0	0.0
35-39	5	27.8	0	0.0
40-44	3	16.7	0	0.0
45+	3	16.7	0	0.0
Total	18	100	2	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	0.3	0	0.0	1	0.2
18-19	22	5.7	1	8.3	23	5.7
20-24	114	29.3	1	8.3	115	28.7
25-29	91	23.4	4	33.3	95	23.7
30-34	57	14.7	1	8.3	58	14.5
35-39	55	14.1	2	16.7	57	14.2
40-44	28	7.2	3	25.0	31	7.7
45+	21	5.4	0	0.0	21	5.2
Total	389	100	0	0.0	401	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	2.2	0	0.0	1	1.8
18-19	0	0.0	1	8.3	1	1.8
20-24	9	20.0	1	8.3	10	17.5
25-29	6	13.3	4	33.3	10	17.5
30-34	5	11.1	1	8.3	6	10.5
35-39	13	28.9	2	16.7	15	26.3
40-44	8	17.8	3	25.0	11	19.3
45+	3	6.7	0	0.0	3	5.3
Total	45	100	12	100	57	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	2.3	0	0.0
Crack	0	0.0	0	0.0
Heroin	1	2.3	0	0.0
Methadone	0	0.0	0	0.0
Steroids	40	93.0	0	0.0
Morphine	0	0.0	0	0.0
Unknown	1	2.3	1	100
Total	43	100	1	100

Table 13: Main Drug of Use for All NSP Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	0.7	0	0.0
Crack	0	0.0	0	0.0
Heroin	14	10.0	0	0.0
Methadone	0	0.0	0	0.0
Morphine	0	0.0	0	0.0
Steroids	122	87.1	0	0.0
Unknown	3	2.1	2	100
Total	140	100	2	100

Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	2	0.5	0	0.0
Crack	1	0.3	0	0.0
Heroin	37	9.5	7	58.3
Methadone	0	0.0	0	0.0
Morphine	1	0.3	0	0.0
Steroids	345	88.5	0	0.0
Unknown	4	1.0	5	41.7
Total	390	100	12	100

Table 15: Main Drug of Use for Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta- mine		Cocaine		Heroin		Methadone		Steroids		Unknown	
	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-19	0	0.0	0	0.0	0	0.0	0	0.0	5	4.1	0	0.0
20-24	0	0.0	0	0.0	1	7.1	0	0.0	35	28.7	1	33.3
25-29	0	0.0	0	0.0	2	14.3	0	0.0	29	23.8	2	66.6
30-34	0	0.0	0	0.0	3	21.4	0	0.0	19	15.6	0	0.0
35-39	0	0.0	1	100	3	21.4	0	0.0	15	12.3	0	0.0
40-44	0	0.0	0	0.0	3	21.4	0	0.0	11	9.0	0	0.0
45+	0	0.0	0	0.0	2	14.3	0	0.0	8	6.6	0	0.0
Total	0	0.0	1	100	14	100	0	0.0	122	100	3	100

* % Totals are by drug, not Age Group

PHARMACY NSPs

Table 16: Individuals by Gender

New Clients	n	%
Male	197	90.0
Female	22	10.0
Total	219	100
All Clients		
Male	346	89.9
Female	39	10.1
Total	385	100

Table 17: Individuals by Site

PNSP Site	Individuals	
	n	%
Co-op Bold Street	163	42.3
Co-op Fearnhead Cross	48	12.5
Lloyd’s Pharmacy Earl St	77	20.0
Rowlands Thelwall Lane	97	25.2
Total	385	100

Table 18: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	3	1.4	7	1.8
20-24	38	17.4	56	14.5
25-29	46	21.0	76	19.7
30-34	58	26.5	90	23.4
35-39	31	14.2	67	17.4
40-44	30	13.7	57	14.8
45+	13	5.9	32	8.3
Total	219	100	385	100

Table 19: Main drug of Use for All PNSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Crack	0	0.0	0	0.0
Amphetamine	0	0.0	0	0.0
Heroin	101	29.2	5	12.8
Steroids	30	8.7	1	2.6
Unknown	215	62.1	33	84.6
Total	346	100	39	100

Table 20: Year to Date; by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	2	< 1	0	0.0	2	< 1
18-19	26	2.6	4	3.2	30	2.7
20-24	179	17.9	8	6.4	187	16.6
25-29	224	22.4	22	17.6	246	21.8
30-34	189	18.9	40	32.0	229	20.3
35-39	203	20.3	26	20.8	229	20.3
40-44	116	11.6	13	10.4	129	11.4
45+	63	6.3	12	9.6	75	6.7
Total	1,002	100	125	100	1,127	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 21: Individuals in Agency and Pharmacy NSP, by Gender

New Clients	n	%
Male	237	91.2
Female	23	8.8
Total	260	100
All Clients		
Male	478	92.1
Female	41	7.9
Total	519	100

Table 22: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	187	89.5
Female	22	10.5
Total	209	100
All Clients		
Male	328	89.1
Female	40	10.9
Total	368	100

*Only known steroid users, based on Agency NSP data and some Pharmacy NSP, have been omitted.

Table 23: Individuals in Agency and Pharmacy NSP , by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	6	2.3	12	2.3
20-24	54	20.8	90	17.3
25-29	55	21.2	107	20.6
30-34	63	24.2	112	21.6
35-39	35	13.5	85	16.4
40-44	32	12.3	70	13.5
45+	15	5.8	43	8.3
Total	260	100	519	100

Table 24: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	1.0	4	1.1
20-24	35	16.7	52	14.1
25-29	44	21.1	68	18.5
30-34	54	25.8	86	23.4
35-39	32	15.3	69	18.8
40-44	30	14.4	58	15.8
45+	12	5.7	31	8.4
Total	209	100	368	100

Table 25: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	4	0.3	0	0.0	4	0.3
18-19	51	3.7	5	3.7	56	3.7
20-24	279	20.5	9	6.7	288	19.3
25-29	310	22.8	27	20.1	337	22.5
30-34	243	17.9	39	29.1	282	18.9
35-39	248	18.2	27	20.1	275	18.4
40-44	143	10.5	15	11.2	158	10.6
45+	83	6.1	12	9.0	95	6.4
Total	1,361	100	134	100	1,495	100

Table 26: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	5,750	14,170	19,740	93,548

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

NSP SERVICE ACTIVITY SUMMARY

Data presented here illustrate service activity across all NSP types including number of transactions, proportion of data that are attributable and a split of activity by NSP type. Individuals by NSP type are also summarised for comparative purposes.

Table 27: All NSP transactions by NSP Type

All Transactions	n	%
Warrington CDT	241	19.5
Pharmacy NSPs	996	80.5
Total	1,237	100

Fig 1: NSP Service Activity; Transactions by NSP Type




Table 28: NSP Transactions, Attributable Data

All Attributable Transactions	n	%*
Warrington CDT	192	16.6
Pharmacy NSPs	966	83.4
Total	1,158	100

*Represents proportion of transactions that were attributable during the current quarter.


Table 29: PNSP Transactions and Individuals by Site

PNSP Site	Transactions		Individuals	
	n	%	n	%
Co-op Bold Street	405	40.7	163	42.3
Co-op Fearnhead Cross	103	10.3	48	12.5
Lloyd's Pharmacy Earl St	209	21.0	77	20.0
Rowlands Thelwall Lane	279	28.0	97	25.2
Total	996	100	385	100

Table 30: All NSP Individuals by NSP Type

All Clients	n	%
Warrington CDT	142	26.9
Pharmacy NSPs	385	73.1
Total	527	100

Fig 2: NSP Service Activity; Individuals by NSP Type



National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2010/11)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or are in contact with treatment services, before this period.

Table 31: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	62	84.9
Female	11	15.1
Total	73	100
All Clients		
Male	585	74.7
Female	198	25.3
Total	783	100

Table 32: Year to Date, by Gender

New Clients	n	%
Male	259	79.7
Female	66	20.3
Total	325	100
All Clients		
Male	603	75.2
Female	199	24.8
Total	802	100

Table 33: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	7	9.6	54	6.9
18-19	5	6.8	24	3.1
20-24	13	17.8	84	10.7
25-29	14	19.2	132	16.9
30-34	15	20.5	182	23.2
35-39	9	12.3	166	21.2
40-44	6	8.2	87	11.1
45+	4	5.5	54	6.9
Total	73	100	783	100

Table 34: Year to Date, Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	35	10.8	57	7.1
18-19	18	5.5	25	3.1
20-24	38	11.7	84	10.5
25-29	50	15.4	135	16.8
30-34	69	21.2	182	22.7
35-39	57	17.5	174	21.7
40-44	32	9.8	89	11.1
45+	26	8.0	56	7.0
Total	325	100	802	100

Table 35: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	61	83.6	737	91.1
White Irish	0	0.0	8	1.0
Other White	1	1.4	15	1.9
White & Black Caribbean	2	2.7	8	1.0
Other Black	0	0.0	3	< 1
Asian	5	6.9	3	< 1
Other Mixed	0	0.0	1	< 1
Caribbean	0	0.0	0	0.0
Chinese	0	0.0	0	0.0
Other	1	1.4	6	< 1
Unknown	3	4.1	2	< 1
Total	73	100	783	100

Table 36: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	35	47.9	526	67.2
Methadone	0	0.0	29	3.7
Other Opiates	2	2.7	26	3.3
Benzodiazepines	1	1.4	5	< 1
Amphetamines	2	2.7	14	1.8
Cocaine	11	15.1	67	8.6
Crack	0	0.0	4	< 1
Hallucinogens	0	0.0	1	< 1
Ecstasy	0	0.0	0	0.0
Cannabis	17	23.3	101	12.9
Antidepressants	1	1.4	0	0.0
Prescription Drugs	4	5.5	6	< 1
Mephedrone	0	0.0	1	< 1
Other/Unknown	0	0.0	3	< 1
Total	73	100	783	100

COMBINED DATASETS

Quarter 4 (2010/11)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSPs (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 37: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	979	81.2
Female	226	18.8
Age Group		
Under 18	54	4.5
18-19	36	3.0
20-24	166	13.8
25-29	219	18.2
30-34	267	22.2
35-39	227	18.8
40-44	143	11.9
45+	93	7.7
Total	1,205	100

Table 38: Year to Date, by Gender and Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	47	2.5	14	4.5	61	2.8
18-19	74	4.0	11	3.5	85	3.9
20-24	327	17.7	30	9.6	357	16.5
25-29	386	20.9	57	18.3	443	20.5
30-34	338	18.3	85	27.2	423	19.6
35-39	344	18.6	62	19.9	406	18.8
40-44	202	10.9	33	10.6	235	10.9
45+	128	6.9	20	6.4	148	6.9
Total	1,846	100	312	100	2,158	100

CROSS-MATCHED DATASETS

Quarter 4 (2010/11)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.

Fig 3: Current Quarter Crossover between Agency NSP and NDTMS datasets




Fig 4: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets




Fig 5: Year to Date Crossover between Agency NSP and NDTMS datasets




Fig 6: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

